Latest News

Roche gets FDA priority review for atezolizumab

PD-L1 (programmed death-ligand 1), which is expressed on tumour cells and tumour-infiltrating immune cells, interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, atezolizumab can trigger activation of T cells, restoring their ability to effectively detect and attack tumour cells. © Genentech


by tg

Roche is expanding its indications in cancer immunotherapy. Following FDA approvals of its PD-L1 checkpoint inhibitor atezolizumab in NSCLC and bladder cancer patients refractive to platinum-based chemotherapy, the Swiss pharma major is awaiting a FDA decision on whether the antibody is suitable as first-line treatment in a further subpopulation of bladder cancer patients.

Based on results of a single arm Phase II study, the FDA granted atezolizumab Priority Review in an additional type of advanced bladder cancer. While the agency granted accelerated market approval in May 2016 for the anti-PD-L1 antibody in patients who were treatment-refractive to platinum-based chemotherapy in neoadjuvant or adjuvant setting, the current priority review extends treatment options. Until April 2017, the agency will decide on the approval of atezolizumab in patients with bladder cancer not eligible for cisplatin chemotherapy (first-line treatment) or disease progression after 12 months of cisplatin therapy before or after surgery.

Roche’s supplemental biologics license application (sBLA) submission for atezolizumab is based on results from the Phase II IMvigor210 study. IMvigor210 is an open-label, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic bladder cancer, regardless of PD-L1 expression. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included duration of response (DOR), overall survival (OS), progression-free survival (PFS) and safety.

New target for lung fibrosis discovered

Seeking for the reason why myofibroblasts, which normally secrete collagen in response to inflammatory signals to repair tissue injury in the lungs,...

Sanofi ends immuno-oncology discovery with Regeneron

Sanofi explained it wanted to gain more financial flexibility to push its own early stage immuno-oncology pipeline. Under the 5-year agreement inked...

BioNtech swallows MAB Discovery antibody unit

Under the terms of the agreement, BioNTech will acquire all assets, employees and proprietary know-how for mAb generation from MAB Discovery....

Diverse cells make up the endothelium

Endothelial dysfunction has been recently highlighted as a hallmark in many severe disorders including cardiovascular diseases. However,...

IMI launches €80m call

The new call of the joint undertaking of the European Commission and the Big Pharma federation EFPIA puts new open access tools for drug development,...

Sugar replacement slows cancer growth

Feeding mannose either alone or alongside chemotherapy through a feeding tube three times a week and continuously via their drinking water was...

British F2G Biotech bags €24m

F2G Biotech said it will be spending most of the assets to push forward pivotal clinical trials of its lead compound Olorofim (F901318), a Phase IIb...